- FDA “Breakthrough Device Designation”
- Tox Study Completion
- WMIC 2019 Poster
- Q&A with Bob Proulx
Positive Results from IBI10103 Phase I Study with MagSense® HER2 Imaging Agent
Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent Imagion Biosystems Limited